Moderna has reported its Q1 earnings, with revenue beating estimates but earnings impacted by a litigation charge, leading to mixed results. The company's revenues have seen strong international momentum, and some investors are revisiting the Q1 results and pipeline milestones. The earnings report has prompted varied reactions, with some outlets discussing the stock's potential as a buy or hold, while others are analyzing it in the context of the broader biotechnology sector.